Shares of BeyondSpring (NASDAQ:BYSI) have been assigned a consensus broker rating score of 1.00 (Strong Buy) from the two brokers that provide coverage for the stock, Zacks Investment Research reports. Two investment analysts have rated the stock with a strong buy recommendation.
Brokerages have set a twelve-month consensus price objective of $56.00 for the company and are anticipating that the company will post ($0.76) earnings per share for the current quarter, according to Zacks. Zacks has also assigned BeyondSpring an industry rank of 189 out of 265 based on the ratings given to related companies.
A number of research analysts have recently commented on the stock. Seaport Global Securities assumed coverage on shares of BeyondSpring in a research report on Tuesday, December 5th. They set a “buy” rating and a $56.00 price target for the company. HC Wainwright set a $60.00 price target on shares of BeyondSpring and gave the company a “buy” rating in a research report on Monday, December 4th. Maxim Group set a $52.00 price target on shares of BeyondSpring and gave the company a “buy” rating in a research report on Thursday, November 30th. Finally, Zacks Investment Research upgraded shares of BeyondSpring from a “sell” rating to a “hold” rating in a research report on Tuesday, January 9th.
BeyondSpring (BYSI) traded up $0.16 on Wednesday, hitting $26.25. 5,862 shares of the stock were exchanged, compared to its average volume of 10,182. BeyondSpring has a 12-month low of $18.50 and a 12-month high of $48.49.
BeyondSpring Company Profile
BeyondSpring Inc, a clinical stage biopharmaceutical company, focuses on the development of cancer therapies. The company is advancing its lead asset, Plinabulin, into a Phase 2/3 clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase 2/3 clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase 3 clinical trial as an anticancer agent in combination with docetaxel in advanced NSCLC; and Phase 1/2 clinical trials with the immuno-oncology agent nivolumab.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BeyondSpring Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeyondSpring and related companies with MarketBeat.com's FREE daily email newsletter.